


Our aim is to get every patient access to
the right treatment at the right time


Through DXRX: The world's first diagnostic commercialisation platform for Precision Medicine



A cloud platform, delivered as a service, on a subscription model




To eliminate these hurdles




- **Established**, provider of services to the world's leading pharmaceutical companies
- **Experts** in diagnostic commercialisation with experience on almost all oncology precision medicine drugs brought to market
- The only **digital platform** – DXRX – bringing together all the stakeholders required to resolve the inefficiencies in the Precision Medicine diagnostics market
- **Unparalleled depth of data**, which combined with our unique data mining tools and algorithms, provide rich real world testing data insights at disease level
- A **global network** of labs and service partners in Precision Medicine diagnostics, not limited by geography
- Focused on Precision Medicine across **all key diseases**

Financial performance



The DXRX platform: our unique diagnostic commercialisation platform for Precision Medicine

- A data-enabled, digital platform, connecting labs, pharma and service providers to collaborate and shape the marketplace, in real time
- Harmonizes multiple global sources of raw data into actionable insights using DDPs®
- Reduces the diagnostic hurdles ensuring that laboratories are test ready for each new Precision Medicine at launch
- Significantly increasing pharma's return on investment on developing new drugs
- Enables physicians to diagnose and deliver the right medicine to each individual patient



We address a large and growing opportunity

- In 2020 it is estimated that the Precision Medicine industry was valued at \$58billion. It has been predicted that the Precision Medicine industry will grow by 9.2% CAGR by 2026 to over \$98billion
- Leading pharma companies working in Precision Medicine include Novartis, Roche/Genentech, Astra Zeneca, Pfizer, BMS, Merck and Amgen
- The addressable market for Diaceutics specific services today is approximately US\$0.25 billion annually based on our current forecast. We expect this to increase to \$0.45 billion annually by 2026, due to an increasing number of brands being brought to market and more budget being spent by pharma on eliminating the testing hurdles



Deborah Davis,
Non-Executive Chair



Peter Keeling,
Chief Executive Officer



Philip White FCA,
Chief Financial Officer



Ryan Keeling,
Chief Innovation Officer



Charles Hindson,
Non-Executive Director



Michael Wort,
Non-Executive Director